⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Supplementary Figure S17 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Tony Georgiev Sara Puglioli Lucrezia Principi Ettore Gilardoni Christian Pellegrino Gabriele Bassi Andrea Galbiati Dario Neri Samuele Cazzamalli

View Full Paper

Ask AI

Bookmark

Share

Key Points

MMAE release was effectively observed in ex vivo biodistribution studies, highlighting its therapeutic potential.
Analysis was conducted 24 hours post systemic administration of the compound in tumor-bearing mice, showing viable results.
The approach utilized Balb/c nude mice models to assess the distribution of CAIX targeted small molecule-drug conjugates.
Findings suggest this novel strategy could significantly advance treatment options for prostate cancer patients.

Implication

Ex vivo biodistribution shows effective MMAE release in prostate cancer models, indicating potential for targeted therapy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Georgiev et al. (2025) studied this question.

synapsesocial.com/papers/68e040f7a99c246f578b3d42 https://doi.org/10.1158/1535-7163.30255236

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S16 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
2Supplementary Figure S14 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
3Supplementary Figure S15 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
4Supplementary Figure S9 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
5Supplementary Figure S13 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025

Supplementary Figure S6 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary Figure S1 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025
Supplementary Figure S10 from PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer2025